Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1

Fernando L-López a, b, c, d, e, #, Andrés Sarmento-Cabral a, b, c, d, e, #, Vicente Herrero-Aguayo a, b, c, d, e, Manuel D. Gahete a, b, c, d, e, Justo P. Castaño a, b, c, d, e, Raúl M. Luque a, b, c, d, e, *

a Maimóndes Institute of Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain
b Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain
c Reina Sofia University Hospital, Cordoba, Spain
d CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Cordoba, Spain
e International Campus of Excellence on Agrifood, CeiA3, Cordoba, Spain

Received: November 9, 2016; Accepted: January 1, 2017

Abstract

Obesity is a major health problem that courses with severe comorbidities and a drastic impairment of homeostasis and function of several organs, including the prostate gland (PG). The endocrine–metabolic regulatory axis comprising growth hormone (GH), insulin and IGF1, which is drastically altered under extreme metabolic conditions such as obesity, also plays relevant roles in the development, modulation and homeostasis of the PG. However, its implication in the pathophysiological interplay between obesity and prostate function is still to be elucidated. To explore this association, we used a high fat–diet obese mouse model, as well as in vitro primary cultures of normal-mouse PG cells and human prostate cancer cell lines. This approach revealed that most of the components of the GH/insulin/IGF1 regulatory axis are present in PGs, where their expression pattern is altered under obesity conditions and after an acute insulin treatment (e.g. Igfbp3), which might have some pathophysiological implications. Moreover, our results demonstrate, for the first time, that the PG becomes severely insulin resistant under diet-induced obesity in mice. Finally, use of in vitro approaches served to confirm and expand the conception that insulin and IGF1 play a direct, relevant role in the control of normal and pathological PG cell function. Altogether, these results uncover a fine, germane crosstalk between the endocrine–metabolic status and the development and homeostasis of the PG, wherein key components of the GH, insulin and IGF1 axes could play a relevant pathophysiological role.

Keywords: insulin • IGF1 • prostate • obesity • prostate cancer

Introduction

The prostate gland (PG) is an exocrine gland tightly influenced by the endocrine milieu, as its development and homeostasis is regulated, for instance, by sexual hormones. Indeed, testosterone, the main sexual hormone responsible for prostate homeostasis, can be locally converted to dihydrotestosterone, which is involved in increasing proliferation and reducing death of PG cells [1–3]. Moreover, a growing body of evidence indicates that the endocrine axis comprising growth hormone (GH), insulin and insulin-like growth factor 1 (IGF1) is locally expressed [4] in the PG and plays a relevant role in its pathophysiology [5, 6]. Thus, earlier studies showed that pituitary-produced GH is essential for PG development, controlling prostate size [7, 8], and local expression of IGF1 and its receptor (IGF1R), in vivo [9, 10] and in vitro [11]. IGF1 is a well-known regulator of cell proliferation, differentiation and apoptosis [12], which is mainly produced by the liver [13], but is also expressed locally within the stromal and epithelial cells of PGs, where it can act as an autocrine/paracrine factor [4]. Interestingly, studies on mouse models have revealed that IGF1 is essential for the appropriate development of the PG and that GH effects are restricted to the stimulation of IGF1 production [14]. Indeed, IGF1 seems to be able to regulate PG at different levels as it has been associated with the development and function of Leydig cells or with the stimulation of GnRH release resulting in LH secretion and expression [15], suggesting an important role on the puberty timing [16]; consequently, IGF1 absence induces vestigial prostate development and very low testosterone levels, which results
in abnormal perinatal androgenization [17]. In addition, GH/IGF1 axis is an important regulatory system for prostatic disorders [4], and its alterations have been linked to prostate cancer development [18]. In line with this, insulin has also been shown to be crucial for the correct development of the PG, inasmuch as lack of insulin in non-obese diabetic mice affects the morphology and function of PGs promoting atrophy of secretory epithelial cells and stroma hypertrophy, leading to development of intraepithelial neoplasia, inflammation and alteration of the secretory process [19]. Furthermore, replacement of insulin in this type-1 diabetic mouse model increased prostate volume, proliferation and apoptosis rate [20], revealing an important role of insulin for prostate growth and homeostasis. Indeed, hyperinsulinemia sensitizes PG to the growth-promoting effects of testosterone [21] and insulin is also important to maintain the β-adrenergic and muscarinic cholinergic signalling in prostate, as treatment with this hormone reestablished the expression these receptors in diabetic rats [22].

PG pathophysiology is markedly influenced by obesity [23–25], a multifactorial chronic disease that represents one of the most serious threats for the global population [26]. Obesity is characterized by the deregulation of multiple endocrine–metabolic systems, which are, at least in part, responsible for the well-known obesity-related metabolic and cardiovascular complications [27] and, even, with the increased obesity-associated cancer risk [28]. Interestingly, obesity courses with the dysfunction of key regulatory systems, including GH, insulin and IGF1 axes, which are crucial for the correct development and maintenance of several organs [29], including the PG. Nonetheless, obesity-associated alterations in GH [29], insulin [30, 31] and IGF1 [32] levels, together with the concomitant insulin resistance [33], have been shown to impact the function of several metabolic organs, are thought to be involved in the increased obesity-associated cancer risk [34–36] and can negatively affect testosterone levels [37–39], the actual influence of obesity and the concurrent changes in insulin and IGF1 levels in the physiology of normal and tumoral prostate is still to be elucidated.

Consequently, similar to that previously demonstrated in other endocrine tissues, such as pituitary [31] and mammary gland [40], it has been suggested that the development of obesity could be associated with a certain degree of insulin resistance in the PG and could influence its pathophysiology, modulating the normal expression of several endocrine–metabolic axis, including GH/IGF1/insulin system components, which play a relevant role under normal and pathological conditions. For this reason, we have used here a combination of molecular, cellular and whole-animal approaches to study the influence of diet-induced obesity on PG insulin management, and on the gene expression profile of the components of the GH/IGF1/insulin systems at the PG level, as well as the direct role of these hormones (insulin and IGF-I) in normal and tumoral prostate cells.

Materials and methods

Animal models

All experimental procedures were carried out in accordance with applicable guidelines and regulations and following the European Regulations for Animal Care under the approval of the University of Cordoba and the Regional Government Research Ethics Committees. C57BL/6J male mice were obtained at weaning from Janvier-Labs (Le Genest-Saint-Ise, France) and used to: (i) establish a model of diet-induced obesity and (ii) isolate and culture normal prostate cells. Animals were housed in sterile filter-capped cages maintained under standard conditions of light (12-hrs light/dark cycle; lights on at 07:00 a.m.) and temperature (22–24°C), with free access to sterilized diet and water. To obtain normal primary prostate cells, 8–12-wk-old C57BL/6J males fed a standard-chow diet were used. To generate the diet-induced obese model, n = 10 mice per group were housed individually and fed, starting at 4 weeks until 23 weeks of age, a low-fat (LF) or a high-fat (HF) diet [Research Diets Inc, New Brunswick, NJ, USA; LF (10% Kcal fat, 70% Kcal carbohydrates, 20% Kcal proteins), HF (60% Kcal fat, 20% Kcal carbohydrates, 20% Kcal proteins); LF and HF were micronutrients matched diets]. Body weights (BW) were measured once a week. Mice were handled daily to acclimatize them to the experimental procedures and personnel 1–2 weeks before blood sampling or killing. At 23 weeks of age, mice were ip injected with vehicle (control group) or insulin (10 U/kg) and 8 min. later and killed by decapitation without anaesthesia (between 08:00–10:00 hrs). Trunk blood was collected, mixed with EDTA and Miniprotease inhibitor (Roche, Barcelona, Spain) and kept in ice until further centrifugation to obtain plasma. Tissues were immediately excised, weighted and snap-frozen in liquid nitrogen. Plasma/tissues were stored at −80°C until posterior analysis. Mice were weighted before killing, and glucose was measured just afterwards.

In vivo evaluation of metabolic status

As previously reported [41], glucose tolerance tests (GTT; 1 mg/g glucose, ip) were carried out after overnight fasting two weeks before sacrifice, and insulin tolerance tests (ITT; 1 ml/kg Novolin, ip) were performed under ad libitum fed conditions 1 week before killing (in both cases, beginning between 08:00 and 09:00 a.m.). Ten mice/group (HFD and LFD) were used for this evaluation.

Determination of whole body composition

Whole body composition (fat and lean mass percentage) was assessed using a Body Composition Analyser E26-240-RMT (EchoMRI LLC, Houston, TX, USA) the day before killing (22 weeks of age), as previously reported [42]. Ten mice/group (HFD and LFD) were used for this evaluation.

Assessment of circulating hormones and metabolites

Blood glucose was assessed by glucometer (Accu-Chek system; Roche Diagnostics, Barcelona, Spain), Gh (EZRIGH145K, sensitivity 0.07 ng/ml; Millipore, Billerica, MA, USA), insulin (EZRMI-13K, sensitivity 0.2 ng/ml; Millipore), IGF1 (AC-18F1, Immunodiagnostic Systems, sensitivity 63 ng/ml; Fountain Hills, AZ, USA), leptin (EZML-82K, sensitivity 0.05 ng/ml; Millipore) and corticosterone (AC-14F1, Sensitivity 0.55 ng/ml Immunodiagnostic Systems, Boldon, UK) levels were assessed using ELISA kits. Ten mice/group (for insulin determination) or 4–5 mice/
group (for leptin, Gh, Igf1 and corticosterone determinations) were used. All details regarding the protocol, specificity, detectability and reproducibility for each assay can be accessed at the websites of the indicated companies.

**Normal primary prostate cell cultures from mice**

PGs (n = 2–3 pooled PGs/experiment, four separate experiments, 3–4 wells/treatment) were dispersed into single cells [following an adapted protocol from [43, 44]] and plated at 125,000 cells/well in DMEM with 4.5 g/l glucose and D-Valine (SeraLab, West Sussex, UK), supplemented with 10% foetal bovine serum (FBS), 1% antibiotic-antimycotic, and 2 mM L-glutamine (Sigma-Aldrich, St. Louis, MO, USA) at 37°C and 5% CO₂. After 24 hrs, primary prostate cells were pre-incubated in serum-free medium for 2 hrs, and subsequently, the medium was replaced with serum-free medium containing medium alone (control), Igf1 or insulin [Sigma-Aldrich, 10 nM, doses selected according to previous studies implemented by our group [45–48]]. Culture cells were incubated for 24 hrs, and then total RNA was extracted.

**Prostate cell lines**

Two widely accepted human PCA-derived cell lines, one androgen independent (PC3, ATCC® CRL-1435™) and one androgen sensitive (LNCaP; ATCC® CRL1740™) were used. PC3 cells were cultured in RPMI-1640 (Lonza, Basel, Switzerland) complemented with 10% FBS, 1% antibiotic-antimycotic and 2 mM L-glutamine. LNCaP cells were cultured in RPMI-1640 supplemented with glucose (final concentration of 4.5 g/l) and complemented with 10% FBS, 1% antibiotic-antimycotic and 2 mM L-glutamine. Cell lines were validated by short tandem repeat analysis (STR; GenePrint® 10 System, Promega, Barcelona, Spain) and checked for mycoplasma contamination by PCR as previously reported [49].

**Proliferation assays**

Cell proliferation was determined by Alamar-Blue colorimetric assay (Invitrogen, CA, USA) as previously reported [50]. Briefly, 3,000-5,000 cells/well (3–5 individual experiments, 4 wells/treatment) were seeded in 96-well plates. Then, cells were 24 hrs-starved (serum-free-medium) and proliferation rate measured, every 24 hrs, for the following 4 days. On the day of measurement, cells were incubated for 3 hrs in 10% Alamar-Blue/RPMI without FBS and then Alamar-Blue reduction was measured in FlexStation III (Molecular Devices, Madrid, Spain), exciting at 560 nm and reading at 590 nm. Medium with Alamar-Blue was replaced with fresh medium with treatments (insulin or IGF1) immediately after each measurement. Results are expressed as percentage versus control (cell without treatment).

**Migration capacity assay**

The ability of PC3 cells to migrate was evaluated by wound-healing technique as previously reported [51]. Briefly, cells were plated at sub-confluence in 12-well plates (four individual experiments, two wells/treatment). Confluent cells were serum-starved for 24 hrs, and then a wound was made using a 100-µl sterile pipette tip. Cells were rinsed in PBS and incubated for 16 hrs in medium without FBS in the presence of insulin or IGF1 or medium alone (control group). Migration was calculated by the difference between the wound area before and 16 hrs after the treatment using ImageJ (RSB, Bethesda, MD, USA). Three experiments were performed in independent days, in which 3–4 random pictures along the wound were acquired.

**RNA extraction, reverse transcription and quantitative real-time PCR (qPCR)**

Details of RNA extraction, quantification and reverse transcription have been previously reported elsewhere [52, 53]. Specifically, total RNA from fresh pituitary and PG tissues (5 mice/group: LFD and HFD, vehicle or insulin treated) was isolated using Absolutely RNA Miniprep Kit (Agilent, CA, USA), and RNA from primary prostate cell cultures and human cell lines with TRI Reagent (Sigma-Aldrich), both followed by DNase treatment. Total RNA concentration and purity were assessed using Nanodrop-2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). Total RNA (1–2 µg) from each sample was reverse-transcribed using random hexamer primers and the cDNA First Strand Synthesis kit (MRF Competences, Hanover, MD, USA).

The development, validation and application of qPCR to measure the expression levels of different mouse transcripts have been previously reported [31]. Briefly, qPCR reactions were performed using the Brilliant III SYBR Green Master Mix and the qPCR Stratagene Mx3000p instrument (Agilent, Santa Clara, CA, USA). Absolute gene expression levels (copy number) were calculated using a standard curve. A No-RT sample was used as a negative control. For each qPCR reaction, 10 µl of master mix, 0.3 µl of each primer (10 µM stock), 8.4 µl of distilled H₂O and 1 µl of cDNA (100 ng) were mixed with a program consisting of the following steps: (i) 95°C for 3 min., (ii) 40 cycles of denaturing (95°C for 20 sec.) and annealing/extension (61°C for 20 sec.) and (iii) a graded temperature-dependent dissociation step (55°C to 95°C, increasing 0.5°C/30 sec.). To control for variations in the amount of RNA used and the efficiency of the RT reaction, the expression level of each transcript was adjusted by a Normalization Factor (NF) in each sample obtained from the expression levels of three housekeeping genes (β-actin, and cyclophilin for mice samples, and β-actin, GAPDH and HPRT for human cell line samples) using the Genorm program. Expression level of these housekeeping genes did not differ between experimental groups in the tissues analysed (data not shown). Specific primers (Table S1) for the mouse transcripts used were designed with the Primer3-software.

**Western blot**

Tissues (liver and PG, 5 mice/group) were homogenized in RIPA Buffer. Protein concentrations were assessed using Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA). Samples (20 µg) were mixed with 2× Laemmli buffer, boiled and separated on 10% acrylamide gels, and electrophoretically transferred to Hybond-ECL nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA). Blots were blocked in 5% nonfat-dry milk (w/v) dissolved in Tris-buffered...
saline containing 0.1% Tween-20 (TBS-T) and incubated overnight (4°C) with primary antibodies (1:1000) against phospho-Ser473 Akt (CS92715; Cell Signaling, Beverly, MA, USA) or total Akt (CS9272; Cell Signaling) in TBS-T, 5% nonfat-dry milk. Then, blots were incubated with HRP-conjugated, goat-anti rabbit IgG (1:2000; CS70745; Cell Signaling) in 5% dry milk, TBS-T for 1 hr, washed and exposed (5 min.) to Clarity Western-ECL Blotting-Substrate (1705060; Bio-Rad). Films were scanned using Bio-Rad Gel DocTM EQ system and images were analysed using ImageJ.

Statistical analysis

Samples from all groups were processed at the same time. All values are expressed as mean ± S.E.M. or compared with the corresponding controls (set at 100%). All data were tested for normal distribution prior to further analysis. When two groups were compared, t-tests were used to assess significant differences. Multiple groups (BW gaining curves) were compared using a two-way ANOVA followed by post hoc analysis (Tukey). Correlations between BW and phospho-AKT levels were assessed by Pearson’s correlation test \( P < 0.05 \) and were considered significant. All statistical analyses were performed using the GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA).

Results

As illustrated in Figure 1A, after 5 weeks of feeding, HFD-fed mice already exhibited a significantly higher BW, which remained elevated until killing. Obese mice also presented significantly lower lean mass and higher body fat mass, by NMR, compared to controls (Fig. 1B). This was also consistent with the observed increase in all fat depots weight measured (i.e. visceral, subcutaneous, retroperitoneal, mesenteric and brown fat), liver weight (Table S2), and higher circulating leptin levels (Fig. 1C). Consequently, mice fed a HFD presented a worse GTT (Fig. 1D; left panel) and ITT (Fig. 1E; left panel) profile compared to the LFD controls, as glucose levels were higher in the GTT in response to glucose, and insulin was more inefficient to reduce glucose levels during the ITT in the HFD group. These results were further supported by the areas under curves (AUC) in both tests (Fig. 1D/E; right panels). Accordingly, the model generated displayed hyperglycaemia and hyperinsulinemia, as basal glucose and insulin...
levels under fast and fed conditions were significantly increased in blood of HFD mice compared with LFD mice (Fig. 1F and G, respectively). Furthermore, in support to the GTT and ITT data, insulin levels were increased 30 min. after glucose injection in LFD mice, but not in HFD mice, suggesting that pancreas of HFD-fed mice is not appropriately responding to the high glucose levels during the GTT (Fig. 1H). Finally, obese mice presented higher IGF1 and corticosterone levels, whereas GH levels tended to be lower in HFD fed animals (Table S2).

The PG become insulin resistant under obesity conditions

As expected, glucose levels were significantly lower in mice fed a LFD and HFD injected with insulin (Fig. 2A). However, the percentage of reduction in HFD mice was smaller than in LFD animals (40% of reduction in HFD-insulin treated compared to HFD-vehicle versus 80% of reduction in LFD-insulin treated compared to LFD-vehicle), which supports the state of insulin resistance of the HFD mice. Moreover, HFD mice presented higher basal glucose levels under vehicle- and insulin-treated conditions than the corresponding LFD group (Fig. 2A). Then, to determine whether the PG is an organ sensitive to insulin actions as is the case of the liver, adipose tissue or muscle [31], we analysed the levels of AKT phosphorylation in PGs and livers (used as reference-control) in vehicle- and insulin-treated mice under LFD and HFD conditions (Fig. 2B). This showed that, although AKT phosphorylation was significantly increased in mice fed with LFD and HFD in response to insulin treatment compared with their respective vehicle-treated controls, livers of obese mice were resistant to insulin action, for their increment in phospho-AKT levels was significantly lower than that observed in LFD mice (9.2-fold induction on insulin-treated LFD compared to vehicle-treated LFD mice versus 3.2-fold induction on insulin-treated HFD compared to vehicle-treated HFD mice). Remarkably, we found that the PG is also an organ that

![Fig. 2](image_url)
Expression of components of the GH, insulin and IGF1 axes is regulated in the prostate under obesity conditions and in response to acute insulin treatment

Absolute mRNA copy number of several components of the GH, insulin and IGF1 axes, such as Gh, Ghr Insr, Igf1, Igf1r, Igf1 binding proteins 2 and 3 (Igfbp2 and Igfbp3), and also of the glucose transporter-4 (Glut4), was determined by qPCR in the PG of male mice fed a LFD (control group; Table 1A). This revealed that the components of the GH/IGF1/insulin axes with lower level of expression were Igfbp3 and Gh (i.e., less than 100 copies), followed by Igfbp2, Insr and Glut4, whereas Ghr, Igf1r and Igf1 were expressed at high levels (Igf1 > >Ghr-Igf1r- Glut4 > Insr-Igfbp2 > Gh-Igfbp3). Interestingly, obesity did not alter drastically the expression levels of some of these components except for an increase in Igfbp3, a decrease in Glut4, and a non-significant reduction in Ghr (P = 0.08) levels in the PGs of HFD-fed mice compared to LFD-fed mice (vehicle-treated; Fig. 3A, white columns). Of note, acute insulin injection tended to increase the expression of Igf1r in the prostate of LFD (P = 0.08) and HFD (P = 0.06) mice as well as to decrease the expression of Gh (P = 0.06) and Igfbp3 (P < 0.05) only in the prostate of obese (HFD conditions) mice (Fig. 3A, black versus white columns).

To determine whether the changes observed at the PG level under obesity conditions and in response to an acute insulin treatment were tissue specific, we performed the same analysis in the pituitaries of these mice, a tissue where the components of the GH, insulin and IGF1 axes are expressed [31, 54]. All the components of these regulatory axes were highly expressed at the pituitary level of adult male mice fed a LFD (control group; Table 1B; Gh>>Igf1r/Igfbp3 >> Insr-Igf1 ≥ Igfbp2 ≥ Ghr>Glut4), and these levels were always higher than those observed at the PG level, except for Glut4 that presented lower expression levels (Table 1A/B). As expected [31], Gh levels were significantly reduced in the pituitary of obese mice (Fig. 3B; white columns). Moreover, the results of mice fed a HFD versus LFD at the pituitary level revealed a non-significant reduction in Ghr (P = 0.08; similar result in PGs) and Igf1r (P = 0.07), as well as a significant decrease in Glut4 expression levels (similar in PGs) (Fig. 3B; white columns). Interestingly, and in contrast to that found at the PG level, acute insulin injection did not induce any specific regulation in the pituitary expression of any component of the Gh, insulin and Igf1 axes analysed of mice fed a LFD or a HFD (Fig. 3B).

To complement these results, plasmatic levels of Gh and Igf1 were determined in these groups of mice. Specifically, no differences in circulating Gh levels were found (Fig. 3C). In contrast, circulating Igf1 levels were significantly increased in obese versus lean vehicle-treated animals (Fig. 3D; white columns), whereas after an acute insulin injection, Igf1 levels only decreased significantly in insulin-treated HFD mice compared with vehicle-treated HFD mice (Fig. 3D; black versus white columns).

Direct effects of insulin and IGF1 in normal and tumoral prostate cells

To assess the direct role of insulin and IGF1 in the expression of different components of the GH/insulin/IGF1 axes and their implications in key functional parameters of prostate cells such as cell proliferation, migration and PSA secretion, we used normal-mouse and tumoral-human prostate cells as models. Particularly, treatment with Igf1 or insulin (24-hrs incubation) of mouse normal primary prostate cell cultures did not alter the expression of their receptors (Igf1r and Insr; Fig. 4A, left panel), whereas Igf1, but not insulin, treatment decreased Ghr expression (Fig. 4A). Moreover, insulin treatment tended to increase Igfbp3 expression (P = 0.09) in mouse normal primary prostate cell cultures (Fig. 4A, right panel).

In the case of human prostate cancer cell lines (PC3 and LNCaP), 24-hrs treatment with IGF1 and insulin reduced (or tended to reduce) the expression of IGFR1, INSR and GHR (Fig. 4B, left panels), whereas only insulin increased the expression levels of Igfbp3 in

Table 1 Absolute mRNA copy number levels (adjusted by a normalization factor derived from the expression of three housekeeping genes) of the components of the GH, insulin and IGF1 axes on the pituitary and prostate glands of male mice fed a LFD. Data represent means number of copies ± S.E.M. (n = 5)

|          | A) Prostate LFD (n = 5) | B) Pituitary LFD (n = 5) |
|----------|------------------------|--------------------------|
| Gh       | 108.7 ± 57.38          | 5.2 × 10² ± 5.5 × 10⁵    |
| Ghr      | 526.4 ± 112.1          | 1712 ± 169.8             |
| Igf1     | 1387 ± 313.1           | 2154 ± 129.4             |
| Igf1r    | 379.8 ± 61.9           | 16600 ± 1391.8           |
| Igfbp2   | 118.1 ± 23.4           | 2016 ± 573.8             |
| Igfbp3   | 31.7 ± 4.4             | 14620 ± 1221.2           |
| Insr     | 128.4 ± 8.9            | 3116 ± 179.4             |
| Glut4    | 222.4 ± 27.9           | 80.9 ± 10.9              |
Fig. 3 Effects of HFD and acute insulin injection on the expression profile of the prostate glands. mRNA expression level of \( \text{Gh} \), \( \text{Ghr} \), \( \text{Igf1} \), \( \text{Igf1r} \), \( \text{Igfbp2} \), \( \text{Igfbp3} \), \( \text{Insr} \) and \( \text{Glut4} \) was determined by qPCR in the prostate (left panels) and pituitary (right panels) glands of LFD- and HFD-fed male mice injected with vehicle (white columns) or insulin (black columns) for 8 min. Values represent absolute copy number adjusted by a normalization factor (NF; calculated from the expression levels of HPRT, cyclophilin and \( \beta \)-actin) (A). Circulating levels of GH and IGF1 of the four groups were determined at killing (B). Values represent mean ± S.E.M. (\( n = 4-5 \) mice/group). Asterisks indicate values that are significantly differ (\( *P < 0.05 \)).

© 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
LNCaP cells (Fig. 4B, right panel). Moreover, IGF1, but not insulin, treatment significantly increased cell proliferation in PC3 and LNCaP cells (Fig. 4C). In the case of PC3, but not LNCaP, cells, this was consistent with the prominent effect of IGF1 versus insulin treatment on the mRNA levels of two relevant proliferation markers (Ki67 and PTTG), whereas TP53 mRNA levels were not altered (Fig. 4D). Finally, IGF1 and insulin also increased the migration capacity of PC3 cells (Fig. 4E; 16-hrs treatment).

**Discussion**

Obesity is a major health problem associated with severe comorbidities and with drastic impairment of the functioning of several metabolic organs [27, 29]. In this scenario, recent studies have demonstrated that obesity induced by high-fat diets promotes structural and metabolic changes in the PG [23–25], altering stromal and matrix ultrastructure, as well as the appropriate signalling and
modulation by different regulators [23–25]. Although androgen (mainly testosterone) and oestrogen signalling may represent the primary controllers of PG function under normal and pathological conditions [24], the components of the GH, insulin and IGF1 axes have been also shown to play relevant roles in the development, modulation and homeostasis of the PG [4, 19, 20]. However, while these neuroendocrine regulatory systems are drastically altered under extreme metabolic conditions such as obesity [29], wherein they associate with key obesity-associated morbidities [e.g. insulin resistance [55]], their implication and regulation in the PG under obesity conditions have not been fully explored hitherto. Accordingly, the present study was devised to determine: (i) whether the PG become insulin resistant under obesity conditions in mice, for this may entail important pathophysiological implications, given the relevant role of insulin in the development and normal function of this gland [19, 20, 22]; (ii) if the expression pattern of the components of the GH, insulin and IGF1 regulatory axes might be altered in the PG under obesity conditions (as occurs in other endocrine organs [31]), and also in response to an acute insulin treatment; and finally, (iii) the direct role of insulin and IGF1 in the control of normal and pathological PG cell function using primary prostate cell cultures from mice and cultured human cell lines as experimental models.

To achieve these objectives, we first developed a classic mouse model of diet-induced obesity by feeding male (C57BL/6J background) mice a HFD, and compared to those fed a LFD starting at 4 weeks of age. This model has been widely used as a mouse model of obesity and insulin resistance, as they easily gain weight and develop diet-induced diabetes [56, 57]. Specifically, we found that the group fed a HFD already presented a significantly higher BW 5 weeks after the start of the diet, and maintained this difference until the day of killing. Of note, the BW gain displayed by the HFD mice was associated with a reduction in the lean mass and an increase in fat body mass and leptin levels, compared to the control group, confirming the obese phenotype. As expected, HFD-fed mice also presented a worst glucose clearance profile and insulin resistance, as indicated by the higher areas under the curve of the GTT and ITT tests in this group compared to the control (LFD) group. Supporting these results, the glucose and insulin levels in fast and fed condition were both higher in the HFD group than in the LFD group, suggesting that the capacity of the pancreas of HFD-fed mice to respond to metabolic insults was impaired. Consistent with this idea, our data demonstrate that HFD-fed mice displayed a clearly impaired glucose-stimulated insulin secretion (GSIS), as LFD-fed mice exhibited a clear insulin increment in response to the glucose bolus, whereas, in the HFD mice, this rise was completely blunted. Additionally, to confirm the status of peripheral insulin resistance, mice fed a LFD and HFD were injected with insulin and, 8 min. later [31], organs were harvested to determine the phosphorylation levels of a classic insulin-responsive signalling pathway (AKT, [58]). Analysis of the livers of these mice confirmed the peripheral insulin resistance induced by the HFD feeding. Moreover, we demonstrated, for the first time, that the PG, similarly to that observed in other organs [31], develops a drastic insulin resistance in conditions of obesity, as demonstrated by the severely reduced increments of AKT phosphorylation in response to an acute insulin injection, thus reinforcing the idea of a relevant crosstalk between the alterations in the endocrine–metabolic status (i.e. obesity) and the dysregulation of the normal metabolic homeostasis of the PG.

To further explore the consequences of the HFD-induced obesity at the PG level, we carried out a comprehensive characterization of the expression and regulation of key components of the GH, insulin and IGF1 regulatory axes in mice fed a LFD or a HFD, and compared them with the changes observed in the pituitary, an endocrine gland wherein these regulatory axes also play relevant functional roles [45, 48, 59]. This analysis confirmed and expanded previous data indicating that the majority of the components of the GH, insulin and IGF1 regulatory axes were expressed in PGs. Particularly, these results are consistent with previous studies showing that the Ghr is expressed in the prostate [60], whereas, to the best of our knowledge, our study represents the first piece of evidence showing that Ghr is also locally expressed in this gland. In this sense, as previous studies have indicated that the role of circulating GH in the PG is circumscribed to the stimulation of the local production of IGF1 [4], these data might also suggest the existence of an autocrine/paracrine GH/GHR loop potentially able to stimulate IGF1 production from the PG. Indeed, our results confirmed previous findings showing the expression of igf1, Igfr and Insr at the PG [4, 9, 10], and demonstrated the local expression of other components of the IGF1/insulin system such as various Igfbps (Igfbp2 and Igfbp3) as well as of other associated proteins, as is the case of the glucose transporter Glut4. Most importantly, as previously observed in other tissues [31, 40], our results indicate that the expression pattern of the components of the GH, insulin and IGF1 regulatory axes can be finely modulated in the PG by environmental factors such as the diet. Particularly, we found that PGs of obese mice presented altered expression levels of Ghr and Glut4, which were similar to those observed in the pituitary of obese mice, but also prostate-specific changes, such as an up-regulation in Igfbp3 expression, which might have some pathophysiological implications as will be further discussed below. Remarkably, the data presented herein also provide primary evidence that an acute insulin treatment can specifically modulate the expression of specific components of the GH, insulin and IGF1 axes at the PG, but not the pituitary level, and that these changes could be different in lean versus obese mice. Namely, whereas Igfr expression tended to be higher in insulin-treated LFD and HFD animals, Igfbp3 expression was severely decreased only in HFD-fed mice after the acute insulin injection. Although the pathophysiological implications of the changes mentioned herein are still to be elucidated further, these results support the existence of a tight crosstalk between the endocrine–metabolic milieu and the normal homeostasis of the PG, wherein the GH, insulin and IGF1 regulatory axes could to play a important role.

These latter results might be of particular interest, owing to the fact that it has been demonstrated that GH, IGF1 and insulin axes play a direct role in the control of the pathophysiology of prostate cells and, therefore, any dysregulation in the normal expression pattern of these regulatory systems, as the observed under obesity conditions in this study might have some potential pathological implications. Indeed, there is currently strong evidence supporting the existence of a clear association between alterations in the metabolic and hormonal status (e.g. changes in circulating insulin, IGF1 and/or GH levels, obesity, diabetes) and a higher risk of developing, and an increased
aggressiveness of, certain types of cancer, including prostate cancer [61–63]. In this sense, we did not find any difference in circulating Gh levels in obese mice, likely because of the intrinsic pulsatility of Gh secretion. In contrast, it is plausible that the elevated levels of circulating Igf1 and insulin found in obese versus lean vehicle-treated mice could have some pathophysiological implications at the PG level. Indeed, we used mouse primary prostate cell cultures to determine whether insulin and/or Igf1 could directly be responsible for the alterations in the expression of the components of the GH, IGf1 and insulin axes observed in vivo in obese mice (i.e. down-regulation of Ghr and up-regulation of Igfbp3). Interestingly, similar to that found in vivo, we found that the expression of Ghr (but not Igf1r or Insr) was reduced in response to Igf1, but not insulin treatment in mouse primary prostate cell cultures. Thus, the reduction in Gh signalling at the PG level found in vivo (and also in vitro in response to Igf1 treatment) may suggest the existence of a negative feedback in this gland, similar to that previously reported at the pituitary [64], wherein excessive circulating Igf1 levels could be exerting a regulatory negative feedback by downregulating of Gh signalling. Moreover, similar to that found in vivo, we also observed that Igfbp3 expression tended to be increased in response to insulin in mouse primary prostate cell cultures, which might have some pathophysiological implications, as Igfbp3 has been shown to be overexpressed in tumoral versus normal-benign PGs and is associated with enhanced malignancy features in prostate cells [65–67]. Therefore, although insulin and IGf1 did not exert identical actions, likely because of the dissimilar affinity of both hormones to insulin and IGf1 receptors (forming homo- and hetero-dimers) [68], these data reinforce the contention that insulin and IGf1 are main regulators of PG physiology, and anticipate that the changes observed in obese mice could play a role in the pathogenesis of the PG. Nonetheless, the data presented herein using androgen-independent and androgen-sensitive prostate cancer cell lines (PC3 and LNCaP) demonstrate that IGf1 and/or insulin can similarly modulate some parameters related to prostate cancer pathophysiology such as proliferation and expression of relevant receptors (INSR, IGFR or GHR), and therefore, we might speculate that these actions of insulin and IGf1 might be androgen independent. Particularly, both hormones altered the expression of INSR, IGFR and GHR and increased the capacity of PC3 cells to migrate. In addition, IGf1 was also able to promote the proliferation of both LNCaP an PC3 cells, which could be likely associated with the prominent increase in the expression of two proliferation markers (PTTG and Ki67), at least in the case of PC3 cells. Remarkably, these results are in partial agreement with a previous report showing a role of insulin and IGf1 in the modulation of some of these tumoral parameters [69], in particular a consistent stimulatory effect of IGf1 and insulin on cell proliferation in several prostate cancer cell lines [69]. Therefore, these results, together with other studies reporting a clear association of the risk of prostate cancer with IGf1 levels, insulin levels and/or insulin resistance [18, 34–36, 70], reinforce the importance of these two hormones in the pathophysiology of the PG and suggest their putative utility in the prognosis and/or treatment of prostate cancer. In addition, from a clinical point of view, as metformin, an antidiabetic drug associated with a reduction in PCa risk [71, 72], has been shown to reduce insulin levels and insulin resistance, the results presented herein could invite to suggest that one of the putative mechanisms that might help to explain the beneficial actions of metformin on PCa development and progression might be the reduction in insulin resistance at the PG level.

Altogether, the data presented herein demonstrate, for the first time, that the PG becomes severely insulin resistant under diet-induced obesity in mice and that most of the components of the GH, insulin and IGf1 regulatory axis are present in the PG, wherein their expression pattern is altered under diet-induced obesity and after an acute insulin treatment. These data, together with the in vitro results confirming and expanding the direct role of insulin and IGf1 in the control of normal and pathological prostate cells, demonstrate a relevant crosstalk between the endocrine–metabolic status and the development and homeostasis of the PG, wherein some components of the GH, insulin and IGf1 axes could play a significant pathophysiological role.

Acknowledgements

This work was supported by the following grants: BIO-0139, CTS-1406, PI-0639-2012, PI-0541-2013 (Junta de Andalucía), P113-00651, P116/00264, PIE14/00005 (Instituto de Salud Carlos III, and co-funded by European Union (ERDF/ESF, “Investing in your future”), BFU2013-43282-R (Ministerio de Economía y Competitividad), CIBERobn and Ayuda Merck Serono 2013.

Conflict of interest

The authors confirm that there are no conflicts of interest.

Author contribution

F.L-L., A.S-C. and R.M.L conceived and designed the project. F.L-L., A.S-C., V.H-A. and R.M.L. acquired the specimens and/or data. F.L-L., A.S-C., V.H-A. and R.M.L. performed the analysis and interpretation of data. F.L-L., A.S-C., M.D.G. and R.L.H wrote the manuscript. V. H-A. and J.P.C. revised the manuscript. F.L-L., A.S-C. and R.M.L. performed the statistical analysis. J.P.C and R.M.L obtained funding. R.M.L supervised the work.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Table S1 Specific set of primers used for the amplification of mouse and human transcripts by qPCR.

Table S2 Characterization of the high-fat diet-induced obese model. Data represent means ± S.E.M. (n = 4–9). Numbers in parentheses indicate the number of samples analyzed for each parameter. Asterisks indicate values that differ between HFD and LFD (*P < 0.05; ***P<0.001).
References

1. Nukui M, Takada H, Nakagawa S. Cross-sectional analysis between prostate volumes and serum sex hormones in Japanese men attending a urological clinic. Aging Male. 2016; 19: 148–54.

2. Bosland MC, Mahmoud AM. Hormones and prostate carcinogenesis: androgens and estrogens. J Carcinog. 2011; 10: 33.

3. Esfahani A, Kendall CW, Bashyam B, et al. The effect of physiological concentrations of sex hormones, insulin, and glucagon on growth of breast and prostate cells supplemented with unmolded human serum. In Vitro Cell Dev Biol Anim. 2010; 46: 856–62.

4. Favaro WJ, Cagnon VH. Effect of combined hormonal and insulin therapy on the steroid hormone receptors and growth factors signaling in diabetic mice prostate. Int J Exp Pathol. 2010; 91: 537–45.

5. Correa LL, Lima GA, Paiva HB, et al. Prostatic cancer and acromegaly. Arq Bras Endocrinol Metabol. 2009; 53: 963–8.

6. Correa LL, Balarini Lima GA, Cavallieri SA, et al. Prostatic disorders in acromegalic patients experience of a Brazilian center. Int Braz J Urol. 2013; 39: 393–401.

7. Colao A, Spiezia S, Di Somma C, et al. Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. Eur J Endocrinol. 2000; 143: 61–9.

8. Colao A, Marzullo P, Spiezia S, et al. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly. GH deficiency, and healthy subjects. J Clin Endocrinol Metab. 1999; 84: 1986–91.

9. Reiter E, Kecha O, Hennuy B, et al. Growth hormone directly affects the function of the different lobes of the rat prostate. Endocrinology. 1995; 136: 3338–45.

10. Reiter E, Bonnet P, Sente B, et al. Growth hormone and prolactin stimulate androgen receptor, insulin-like growth factor-I (IGF-I) and IGF-I receptor levels in the prostate of immature rats. Mol Cell Endocrinol. 1992; 88: 77–87.

11. Bidosse M, Karry R, Weiss-Messer E, et al. Growth hormone affects gene expression and proliferation in human prostate cancer cells. Int J Androl. 2011; 34: 124–37.

12. Djavan S, Waidert M, Seitz C, et al. Insulin-like growth factors and prostate cancer. World J Urol. 2001; 19: 235–33.

13. Bonefeld K, Molier S. Insulin-like growth factor-I and the liver. Liver Int. 2011; 31: 911–9.

14. Ruan W, Powell-Braton L, Kopchick JJ, et al. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology. 1999; 140: 1984–9.

15. Wolfe A, Divall S, Wu S. The regulation of reproductive neuroendocrine function by insulin and insulin-like growth factor-1 (IGF-1). Front Neuroendocrinol. 2014; 35: 558–72.

16. Cole TJ, Ahmed ML, Preece MA, et al. The relationship between Insulin-like Growth Factor 1, sex steroids and timing of the pubertal growth spurt. Clin Endocrinol. 2015; 82: 862–9.

17. Baker J, Hardy MP, Zhou J, et al. Effects of an IGF1 gene null mutation on mouse reproduction. Mol Endocrinol. 1996; 10: 903–18.

18. Denley A, Cosgrove LJ, Booker GW, et al. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 2005; 16: 421–39.

19. Ribeiro DL, Caldeira EJ, Candido EM, et al. Prostatic stromal microenvironment and experimental diabetes. Eur J Histochem. 2006; 50: 51–60.

20. Favaro WJ, Padovani CR, Cagnon VH. Ultrastructural and proliferative features of the ventral lobe of the prostate in non-obese diabetic mice (NOD) following androgen and estrogen replacement associated to insulin therapy. Tissue Cell. 2009; 41: 119–32.

21. Vikram A, Jena G. Role of insulin and testosterone in prostatic growth: who is doing what? Med Hypotheses. 2011; 76: 474–8.

22. Fukumoto Y, Yoshida M, Dokita S, et al. The reversal effect of insulin on diabetes-induced alterations in beta adrenergic and muscarinic receptors in rat prostate. J Urol. 1993; 149: 1602–6.

23. Ribeiro DL, Pinto ME, Maeda SY, et al. High fat-induced obesity associated with insulin-resistance increases FGF-2 content and causes stromal hyperplasia in rat ventral prostate. Cell Tissue Res. 2012; 349: 577–88.

24. Ribeiro DL, Pinto ME, Rafacho A, et al. High-fat diet obesity associated with insulin resistance increases cell proliferation, estrogen receptor, and PDXK proteins in rat ventral prostate. J Androl. 2012; 33: 854–65.

25. Silva SA, Gobbo MG, Pinto-Fochi ME, et al. Prostate hyperplasia caused by long-term obesity is characterized by high deposition of extracellular matrix and increased content of MMP-9 and VEGF. Int J Exp Pathol. 2015; 96: 21–30.

26. Keller KB, Lemberg L. Obesity and the metabolic syndrome. Am J Crit Care. 2003; 12: 167–70.

27. Barnes LA, Opitz JM, Gilbert-Barness E. Obesity: genetic, molecular, and environmental aspects. Am J Med Genet A. 2007; 143A: 3016–34.

28. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013; 2013: 291546.

29. Berryman DE, Gid CAM, List ED, et al. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol. 2013; 9: 346–56.

30. Cordoba-Chacon J, Gahele MD, Pozo-Salas Al, et al. Peripubertal-onset but not adult-onset obesity increases IGF-I and drives development of lean mass, which may lessen the metabolic impairment in adult obesity. Am J Physiol Endocrinol Metab. 2012; 303: E1151–7.

31. Luque RM, Kineman RD. Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology. 2006; 147: 2754–63.

32. Kreitschmann-Andermahr I, Suarez P, Jennings R, et al. GH/IGF-I regulation in obesity – mechanisms and practical consequences in children and adults. Hormone Res Paediatr. 2010; 73: 153–60.

33. Castro AV, Koika CM, Kim SP, et al. Obesity, insulin resistance and comorbidities? Mechanisms of association. Arg Bras Endocrinol Metabol. 2014; 58: 600–9.

34. Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014; 384: 755–65.

35. Ribeiro R, Monteiro C, Catalan V, et al. Obesity and prostate cancer: gene expression signature of human prostatic adipose tissue. BMC Med. 2012; 10: 108.

36. Parkeitis D, Mochtar CA, Umbas R, et al. The impact of obesity towards prostate diseases. Prostate Int. 2016; 4: 1–6.

37. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005; 90: 2836–41.

38. Barud W, Pietrowska-Swirzcz A, Ostrowski S, et al. [Association of obesity and insulin resistance with serum testosterone, sex hormone binding globulin and estradiol in older males]. Pol Merkur Lekarski. 2005; 19: 634–7.
42. Ghahre-Mehr, M. et al. Erectile dysfunction, obesity, insulin resistance, and their relationship with testosterone levels in eugonadal patients in an andrology clinic setting. *J Androl.* 2010; 31: 263–70.

43. Cordoba-Chacon J, Ghahre MD, Cordoba-Chacon J et al. Obesity alters gene expression for GH/IGF-I axis in mouse mammary fat pads: differential role of cortistatin and somatostatin. *PloS One.* 2011; 10: e0120955.

44. Cordoba-Chacon J, Ghahre MD, Poze-Salas Al et al. Cortistatin is not a somatostatin analogue but stimulates prolactin release and inhibits GH and ACTH in a gender-dependent fashion: potential role of ghrelin. *Endocrinology.* 2011; 152: 4800–12.

45. Ghahre MD, Cordoba-Chacon J, Anadumaka CV et al. Elevated GH/IGF-I, due to somatotrope-specific loss of both IGF-I and insulin receptors, alters glucose homeostasis and insulin sensitivity in a diet-dependent manner. *Endocrinology.* 2011; 152: 4825–37.

46. Lukacs RU, Goldstein AS, Lawson DA et al. Isolation, cultivation and characterization of adult murine prostate stem cells. *Nat Protoc.* 2010; 5: 702–13.

47. Liao CP, Liang M, Cohen MB et al. Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors. *Horm Cancer.* 2010; 1: 44–54.

48. Luque RM, Kineman RD. Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. *Endocrinology.* 2006; 147: 2754–63.

49. Ghahre MD, Cordoba-Chacon J, Lin Q et al. Insulin and IGF-I inhibit GH synthesis and release in vitro and in vivo by separate mechanisms. *Endocrinology.* 2013; 154: 2410–20.

50. Luque RM, Ghahre MD, Valentine RJ et al. Examination of the direct effects of metabolic factors on somatotrope function in a non-human primate model, Papio anubis. *J Mol Endocrinol.* 2006; 37: 25–38.

51. Ghahre MD, Cordoba-Chacon J, Lin Q et al. Insulin and IGF-I inhibit GH synthesis and release in vitro and in vivo by separate mechanisms. *Endocrinology.* 2013; 154: 2410–20.

52. Ghahre MD, Rincon-Fernandez D, Duran-Prado M et al. The truncated somatostatin receptor sstSTMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. *Oncotarget.* 2016; 13: 60110–22.

53. Ghahre MD, Cordoba-Chacon J, Hergueta-Redondo M et al. A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acetyltransferase are overexpressed in breast cancer: potential pathophysiological relevance. *PloS One.* 2011; 6: e23302.

54. Sampedro-Nunez M, Luque RM, Ramos-Levi AHM et al. Presence of sstSTMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. *Oncotarget.* 2016; 7: 6593–608.

55. Pedraza-Arevalo S, Cordoba-Chacon J, Poze-Salas Al et al. Not so giants: mice lacking both somatostatin and cortistatin have high GH levels but show no changes in growth rate or IGF-1 levels. *Endocrinology.* 2015; 156: 1958–64.

56. Cordoba-Chacon J, Ghahre MD, Castano JP et al. Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice. *Am J Physiol Endocrinol Metab.* 2011; 300: E46–54.

57. Werther GA, Hogg A, Oldfield BJ et al. Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computized densitometry. *Endocrinology.* 1987; 121: 1562–70.

58. Kahn BB, Flier JS. Obesity and insulin resistance. *J Clin Invest.* 2000; 106: 473–81.

59. Surwit RS, Kuhn CM, Cochrane C et al. Diet-induced type II diabetes in C57BL/6J mice. *Diabetes.* 1988; 37: 1163–7.

60. Montgomery MK, Hallahan NL, Brown SH et al. Mouse strain-dependent variation in obesity and glucose homeostasis in response to high-fat feeding. *Diabetologia.* 2013; 56: 1129–39.

61. Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. *Mol Med.* 2004; 10: 65–71.

62. Ghahre MD, Cordoba-Chacon J, Anadumaka CV et al. Elevated GH/IGF-I, due to somatotrope-specific loss of both IGF-I and insulin receptors, alters glucose homeostasis and insulin sensitivity in a diet-dependent manner. *Endocrinology.* 2011; 152: 4825–37.

63. Wang Z, Prins GS, Coschigano KT et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. *Endocrinology.* 2005; 146: 5188–96.

64. Ferro M, Terracciano D, Buonerba C et al. The emerging role of obesity, diet and lipid metabolism in prostate cancer. *Future Oncol.* 2017; 13: 285–93.

65. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. *Eur Urol.* 2013; 63: 800–9.

66. Prabhath P, Tewari R, Natu SM et al. Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study. *Indian J Urol.* 2010; 26: 502–6.

67. Romero CJ, Pine-Tweddell E, Sima DI et al. Insulin-like growth factor 1 mediates negative feedback to somatotroph GH expression via POU1F1/CREB binding protein interactions. *Mol Cell Biol.* 2012; 32: 4258–69.

68. Sampson N, Zennmaier C, Heitz M et al. Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation. *Endocrinology.* 2013; 154: 2586–99.

69. Seligson DB, Yu H, Tze S et al. IGFBP-3 nuclear localization predicts human prostate cancer recurrence. *Horm Cancer.* 2013; 4: 12–23.

70. Prager AJ, Peng CR, Lita E et al. Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. *Biomark Med.* 2013; 7: 831–41.

71. Soos MA, Whitaker J, Lammers R et al. Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. *Biochem J.* 1990; 270: 383–90.

72. Heiddegger I, Ofer P, Doppler W et al. Diverse functions of IGF/Insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. *Endocrinology.* 2012; 153: 4633–43.

73. Parkes KI, Mochel CA, Umbas R et al. The impact of obesity towards prostate diseases. *Prostate Int.* 2016; 4: 1–6.

74. Hwang IC, Park SM, Shin D et al. Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis. *Asian Pac J Cancer Prev.* 2015; 16: 596–600.

75. Tseng GH. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. *Eur J Cancer.* 2014; 50: 2831–7.